Noxopharm Ltd. · ASX:NOX
Noxopharm — Investor Presentation (November 2016)
30 slides from Noxopharm's investor presentation, Nov 22, 2016
Slide 1: Corporate Presentation, Nov 2016
For personal use only Corporate Presentation, Nov 2016 ASX: NOX 1
Slide 2: Board: Experienced Team
Board For personal use only Experienced Team Graham Kelly PhD Dr Ian Dixon PhD, MBA CEO & Managing Director Non-Executive Director •Head of research team at University of Sydney that discovered idronoxil in 1992 •Over 20 years’ experience in the biotechnology and medical device industries and •Found
Slide 3: Key metrics
key metrics For personal use only Listed: 9 Aug 2016 Raised: $6m Current: $4.8m Projected runway: mid-2018 3
Slide 4: Securities
securities For personal use only 1. Listed Shares (NOX) 33,560,000 758 OPTIONS 2. Escrowed Shares 464,750 1 1. * @ $0.30: Escrowed until 8/1/17: Expire 28/2/21 Jan 2017 2. ** @ $0.30: Escrowed until 1/4/17: Expire 28/2/21 3. Escrowed Shares 4,261,214 1 3. *** @ $0.30: Escrowed until 1/4/17: Expire 2
Slide 5: Our objective
Our objective For personal use only To bring to market the first drug that sensitises cancer cells to cancer therapies to improve the survival outcomes of standard chemotherapy and radiotherapy and allow effective dosages of standard chemotherapy and radiotherapy to be lowered to non-toxic levels an
Slide 6: In a nutshell
in a nutshell…..... For personal use only In 1971, cancer researchers dreamt of turning cancer into a manageable, non-lethal, chronic disease 45 years later that dream remains elusive for most types of cancer In 1971, chemotherapy and radiotherapy were the standard frontline therapies 45 years later
Slide 7: In a nutshell
in a nutshell…..... For personal use only The dream remains elusive because chemotherapy and radiotherapy are not being used to their full powers …. because damage to healthy cells dictates the highest dose of chemo and radiotherapy that can be used, and that dose is not enough to kill all cancer ce
Slide 8: Noxopharm believes it has the answer
Noxopharm believes it has the answer…..... For personal use only IDRONOXIL: sensitises cancer cells (and only cancer cells) to standard chemotherapy and radiotherapy IDRONOXIL : dramatic level of sensitisation >2000x NOX66: delivering IDRONOXIL in a form designed to maintain its activity in the body
Slide 9: Cancer metrics
Cancer metrics For personal use only 45 years later…. 1971: 2016: President Richard Nixon signs the war Vice-President Joe Biden National Cancer Act continues Announces “Cancer moonshot” Declares “War on cancer” 9
Slide 10: After years of the war on cancer
After After 45 45 years Years of of ‘the warChemotherapy... Cytotoxic on cancer’….... For personal use only 10-year survival rates remain poor for many cancers • Pancreas Little or no • Lung progress • Brain made in • Head and neck survival • Oesophagus outcome for • Stomach cancers of: • Cervix • B
Slide 11: Frontline cancer therapies work by damaging DNA
Frontline cancer therapies work by damaging DNA For personal use only Radiotherapy Chemotherapy Aim is to damage DNA beyond repair cell dies 11
Slide 12: The problem
The problem For personal use only alive Normal cells MAXIMUM TOLERABLE DOSE Highest dose of chemotherapy or radiotherapy that can be delivered is killed determined by the highest dose that can be tolerated by the patient. 12
Slide 13: The problem: Maximum Tolerated Dose
The problem For personal use only The Maximum Tolerated Dose leaves many cancer cells alive High cancer kill eg. cancers of breast, ovary Regardless of cancer type: Normal surviving cancer cells regrow cells Cancer cells to form new, more aggressive cancer Max tolerated dose Low cancer kill eg. canc
Slide 14: The solution
The solution For personal use only To sensitise cancer cells (and only cancer cells) Normal cells Cancer to DNA-damaging effects of cells chemotherapy and radiotherapy so that ALL cancer cells are killed 14
Slide 15: The answer
The answer For personal use only Sensitises all forms of cancer cells (but not healthy cells) by > 2,000x Idronoxil to all standard cytotoxic chemotherapy drugs and radiotherapy 15
Slide 16: Idronoxil history
Idronoxil history History Idronoxil For personal use only Named phenoxodiol. Basis of formation of Discovered in 1992 Novogen Ltd Potent ability to (ASX:1994). sensitise chemotherapy confirmed Phase III study Evidence of anti-cancer (phenoxodiol + Novogen market cap = benefits observed in Enters cli
Slide 17: Idronoxil failed because of Phase 2 metabolism
Idronoxil failed because of Phase 2 The Problem: Phase 2deals Metabolism For personal use only metabolism… .or how the body with water-insoluble drugs Body attaches sugar Drug circulates Aspirin Paracetamol combined to sugar Codeine Steroids D D + S D S D Drug active Drug now inactive Combination D
Slide 18: Idronoxil and Phase 2 metabolism
Idronoxil and Phase 2 metabolism The Problem: Phase 2 Metabolism For personal use only Body attaches sugar Drug circulates combined to sugar + S S Drug now inactive Combination NO Sugar- enters cancer cell Idronoxil remains in removing enzymes S INACTIVE form +++ Sugar- and unable to work attaching
Slide 19: NOX66
NOX66 The Problem: Phase 2 Metabolism For personal use only Body unable to attach sugar S Idronoxil remains in ACTIVE form Proprietary formulation NO Sugar- Interacts with removing enzymes target on outside +++ Sugar- of cancer cell attaching enzymes 19
Slide 20: Clinical Program
Clinical Program For personal use only Cytotoxic chemotherapy Radiotherapy 20
Slide 21: Clinical studies
Clinical studies For personal use only Patients with late-stage cancers that have failed to respond to standard therapies and have no remaining standard treatment options Q1. Can NOX66 result in a significant anti-cancer response where none is expected? Q2. Can Q1. Can NOX66 NOX66 result allow in do
Slide 22: Clinical strategy
Clinical strategy For personal use only To run a broad clinical trial program designed to identify: • chemotherapy? 1. The best treatment combination • radiotherapy? 2. The best purpose of use • Make standard dose work better? • Allow use of lower dose? 3. Optimal cancer type • Prostate, lung, other
Slide 23: Proposed clinical study timeline
AIM: • to have proof-of-concept by end-2017 For personal use only Proposed clinical study timeline • decision on indication for registration studies by end of 1Q-2018 4Q 2016 1Q 2017 2Q 2017 3Q 2017 4Q 2017 1Q 2018 Chemotherapy Study 1 Phase 1a Phase 1b Phase 2a Phase 1b/2a Radiotherapy Study 1 Radi
Slide 24: 5x R&D programs
5x R&D programs For personal use only A. Customized NOX66 formulations for specific cancer types B. Second- and third-generation radio-sensitising drugs C. Use of NOX66 delivery technology for non-oncology purposes 24
Slide 25: Milestones achieved
Milestones achieved For personal use only A. Foundation staff appointed: • In-house clinical affairs team • Scientific team • Manufacturing/chemistry capacity • IR function B. Appointment of key medical advisors C. Clinical trial batch of NOX66 manufactured D. Sites and investigators for 5 clinical
Slide 26: Guidance on key milestones for next months
Guidance on key milestones for next 12 months For personal use only A. Opening of 5 clinical studies (Dec 2017 – June 2018) B. Proof-of-concept data to be reported on from at least 3 clinical studies C. Progress in 5x R&D programs; new IP 26
Slide 27: IP position
IP position For personal use only Idronoxil Structure not patentable. First described by G. Kelly in 1994. Patent lodgement Family of provisional patents lodged. Claims revolve around innovative formulation designed to block Phase 2 metabolism and conserve bio-activity 2nd and 3rd generation R&D pro
Slide 28: Key Messages
For personal use only Key Messages Resistance to chemotherapy/radiotherapy remains the most pressing and largest problem facing cancer patients No drug has come to market that successfully treats this problem WE EXPECT TO KNOW WITHIN 12 MONTHS OF THE SUCCESS OF OUR MISSION AN EXTENSIVE R&D PROGRAM I
Slide 29: Disclaimer
For personal use only Disclaimer 4 This presentation has been prepared by Noxopharm Limited a company proposed to be listed as [ASX:NOX] (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to make an offer or
Slide 30: Contact
For personal use only Contact Dr Graham Kelly Chief Executive Officer graham.kelly@noxopharm.com 30